Pharmacological blockade of NADPH oxidase 4 (nox4), a key regulator of reactive oxygen species in muscle, significantly abrogated cancer cachexia in mice; targeting the SIRT1-nox4 axis seems to be an effective therapeutic intervention for mitigating cancer cachexia (Dasgupta et al., 2020). Here, SIRT1 is linked to cancer.